U.S. Capital Markets Stock News

Uranium Energy (UEC) drew fresh attention after its stock rose 2.1% following RBC Capital’s initiation of coverage on peer Ur-Energy. Investors responded to commentary on U.S. nuclear power and domestic uranium suppliers. See our latest analysis for Uranium Energy. Beyond the latest move, Uranium Energy’s share price has seen a 3.18% 1 day share price return and a 4.95% 7 day share price return, while the 90 day share price return is down 29.89%. Over a longer horizon, the 1 year total...

Revvity stock has delivered a 27.6% decline over the past five years, yet the Discounted Cash Flow (DCF) intrinsic value estimate points to around 22.7% upside from today’s price while earnings based multiples still look rich, leaving investors with a split valuation message. Over five years, Revvity is down 27.6%, which means anyone who bought and held through that period has faced a meaningfully negative total return. The recent integration of Revvity’s Signals AI software with Anthropic’s...

Aehr Test Systems has delivered a very large 5 year return, while the latest valuation checks suggest the stock is not a clear bargain. This puts the current share price under closer scrutiny for investors thinking about what is already priced in. Aehr Test Systems has returned about 11x over 5 years, which means even small changes in expectations can matter a lot for where the stock trades next. Recent orders tied to silicon carbide for electric vehicles and silicon photonics for AI and...

Recent Performance Snapshot for Essential Properties Realty Trust Essential Properties Realty Trust (EPRT) has moved within a relatively tight range recently, with the stock down about 0.6% over the past day and roughly flat over the past week. Over the past month, Essential Properties Realty Trust has gained about 1%, while over the past 3 months the stock has declined roughly 4.5%, offering investors a mixed short term performance profile to consider. See our latest analysis for Essential...

Q32 Bio (QTTB) has completed a $200 million follow on equity offering, shortly after releasing strong 36 week topline data for its bempikibart Phase 2a SIGNAL AA trial in severe alopecia areata. See our latest analysis for Q32 Bio. Q32 Bio’s recent bempikibart data and the follow on offering come after a period of sharp share price moves, with the 7 day share price return of 35.54% and year to date share price return of 436.63% pointing to strong momentum. The 1 year total shareholder return...

Over the last 7 days, the United States market has remained flat, yet it has experienced a significant 20% increase over the past year with earnings forecasted to grow by 18% annually. In this context of overall growth, identifying stocks that are trading below their intrinsic value can present potential opportunities for investors seeking to capitalize on undervalued assets.

In the last week, the United States market has stayed flat, but it has seen a 20% increase over the past year with earnings expected to grow by 18% annually. In this context of steady growth, companies with high insider ownership can be particularly appealing as they often indicate strong confidence from those who know the business best.

Over the last 7 days, the U.S. market has remained flat, though it is up 20% over the past year with earnings forecasted to grow by 18% annually. Investing in penny stocks—often associated with smaller or newer companies—can still open doors to growth opportunities when these stocks are backed by strong financial health. In this context, we will explore several penny stocks that stand out for their financial strength and potential for long-term success.

Coca-Cola FEMSA. de has delivered a strong 141.1% return over the past 5 years, yet the current valuation checks and intrinsic value estimate suggest the stock may still trade at a discount to what its cash flows imply. The 141.1% 5 year return highlights that long term shareholders have already seen substantial gains, which raises the bar for any further upside to be justified by fundamentals. Expectations for steady cash generation from Coca-Cola FEMSA. de's beverage portfolio can support...

Recent trading in iRhythm Holdings (IRTC) has caught investor attention, with the stock closing at US$112.55 and posting declines over the past week, month, and past 3 months, raising questions about how current pricing aligns with fundamentals. See our latest analysis for iRhythm Holdings. For context, iRhythm Holdings’ recent 1 day share price decline of 5.17% and 7 day share price decline of 10.02% sit against a year to date share price return that is down 35.77%, while the 5 year total...

Graphic Packaging Holding (GPK) has drawn fresh attention after launching PaceSetter Ridgeline, an uncoated recycled paperboard product made from 100% recycled fiber and produced at its Waco, Texas mill. See our latest analysis for Graphic Packaging Holding. Despite the launch of PaceSetter Ridgeline and renewed focus on recycled paperboard, Graphic Packaging Holding’s shares trade at $10.33, with the share price down over the year to date, while the 1 year total shareholder return has also...

NOV (NOV) is back on investors’ radar after recent analysis highlighted improving earnings projections, growing market share tied to its drilling technologies, and an order backlog that offers clearer revenue visibility, despite ongoing valuation and margin questions. See our latest analysis for NOV. At a share price of $19.30, NOV has a 7 day share price return of 5.58% after a softer 30 day share price return of 8.66% and a 1 year total shareholder return of 54.42%. Together, these figures...

D.R. Horton stock has delivered a 77.3% return over the past five years. Current checks suggest the shares may still sit below an intrinsic value estimate that points to some undervaluation, and this view is also supported by earnings multiples that lean the same way. Over five years, D.R. Horton has returned 77.3%, which puts recent short-term weakness in a longer-run context for anyone weighing potential valuation upside. Stronger cash generation from its homebuilding operations can...

Independent Bank Corp. recently announced it would release its second-quarter 2026 earnings on July 16, with analysts expecting earnings of US$1.77–US$1.78 per share and revenue of about US$257.73–US$258.95 million. These expectations, alongside a fresh US$0.64 per-share dividend declaration and ongoing analyst estimate revisions, are sharpening investor focus on the bank’s near-term performance. We’ll now examine how the upcoming earnings release and stronger earnings expectations may...

Iridium PNT ASIC launch puts assured timing and location in focus Iridium Communications (IRDM) has moved its assured positioning, navigation, and timing technology from concept to commercial product, launching the Iridium PNT ASIC amid demand from more than 150 organizations across critical infrastructure sectors. See our latest analysis for Iridium Communications. Iridium Communications has paired this product milestone with strong share price momentum, with a 90 day share price return of...

JetBlue Airways (JBLU) is back in focus after launching a new pay later program with ClarityPay that embeds financing into the booking journey and ties directly into its TrueBlue loyalty ecosystem. See our latest analysis for JetBlue Airways. The new ClarityPay partnership comes as JetBlue Airways trades at US$5.33, with the share price showing a 16.12% year to date gain but a 65.28% decline in 5 year total shareholder return. This indicates that recent momentum has not reversed longer term...

Moderna stock has surged 118.5% year to date, yet the company screens as expensive on Simply Wall St's broader valuation checks. This raises a clear question about how much optimism is already built into the current price. The 118.5% gain so far this year suggests investors are pricing in a lot of confidence around Moderna's pipeline and future vaccine revenues. Expectations around upcoming regulatory decisions on its vaccines can support that optimism, but the stock's history of deeper...

Entergy’s carbon capture alliance with Mitsubishi: what investors should watch Entergy (ETR) is drawing fresh attention after signing a memorandum of understanding with Mitsubishi Heavy Industries Group to advance gas turbine, carbon capture and storage projects, while targeting a 50% reduction in overall costs. See our latest analysis for Entergy. Entergy’s recent carbon capture agreement arrives as the stock trades at $115.41, with a year to date share price return of 22.96% and a 5 year...

Teladoc Health stock has had a tough run over the past five years, yet current valuation checks now point to the shares trading at a discount, with the Discounted Cash Flow (DCF) intrinsic value estimate and market multiples both suggesting the market price may sit below what the company’s fundamentals imply. Over the past five years Teladoc Health has declined 94.0%, which puts the current valuation in the context of a long period of weak shareholder returns. Investors are watching how the...

New U.S. tariffs of 25% on thousands of Brazilian imports are set to reshape how agricultural and industrial goods move around the world, with roughly $15b in trade directly in the crosshairs. For investors, that kind of shock can quickly split stocks into potential winners and potential losers as input costs, export routes, and customer demand all adjust. This article walks through three stocks exposed to the tariff story, showing how one could find support from shifting trade flows while...

Live Nation Entertainment (LYV) is back in focus after fresh valuation work using Discounted Cash Flow and revenue multiples suggested the stock trades below an estimated intrinsic value, despite recording a 135.8% total return over the past 5 years. See our latest analysis for Live Nation Entertainment. Over the past year, Live Nation Entertainment has combined a 24.95% year to date share price return with a 24.30% total shareholder return over 12 months. Its 135.82% total shareholder return...

In early July 2026, Thermo Fisher Scientific’s Board authorized a quarterly cash dividend of US$0.47 per share and saw its RapidINTEL Plus DNA cartridge approved by the FBI’s National DNA Index System, while also joining Arcturus Therapeutics to support Phase 3 development and potential commercialization of the ARCT-032 mRNA cystic fibrosis therapy. Together, these developments highlight Thermo Fisher’s mix of shareholder returns, advanced forensic tools linked to the national CODIS...

Kulicke and Soffa Industries stock has delivered a very strong 217.6% return over the past year, yet the current valuation checks suggest the shares are priced at a premium rather than standing out as a clear bargain. Over the last 12 months, Kulicke and Soffa Industries has returned 217.6%, which puts extra focus on whether recent gains already reflect investor optimism. Recent strength in demand across key end markets can support higher earnings expectations, but any disappointment in...

Amkor Technology (AMKR) is back on investor watchlists after a fresh insider trading plan filing, as Chief Financial Officer Megan Faust disclosed plans to sell up to 1,000 shares of common stock acquired through performance awards. See our latest analysis for Amkor Technology. Amkor Technology’s recent insider sales and valuation debate sit against a share price that has climbed 63.56% year to date, with a 90 day share price return of 17.55% but a 30 day share price return that has fallen...